InvestSMART

Nyrada Inc (ASX: NYR) - Announcements

- Current share price for NYR : $0.495

ASX company news and announcements for Nyrada Inc (NYR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Nyrada Inc (NYR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Nyrada Inc (NYR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Nyrada Inc (NYR)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$128 Securities Purchase Plan Results 28 Oct 2026 8:53AM $0.485 $0.495 risen by 2.06%
$128 Quarterly Activities Report and Appendix 4C 19 Oct 2026 9:30AM $0.470 $0.495 risen by 5.32%
$128 PROTECT-MI Phase IIa Clinical Trial Update No 3 16 Oct 2026 8:50AM $0.430 $0.495 risen by 15.12%
$128 Nyrada Receives Positive FDA Feedback 13 Oct 2026 8:16AM $0.480 $0.495 risen by 3.13%
$128 Attaching Options Prospectus 12 Oct 2026 9:22AM $0.480 $0.495 risen by 3.13%
$128 Securities Purchase Plan Offer Booklet 12 Oct 2026 8:20AM $0.480 $0.495 risen by 3.13%
$128 2026 AGM Letter to Shareholders, Notice of Meeting & Proxy 8 Oct 2026 8:16AM $0.500 $0.495 fallen by 1%
$128 Nyrada US Patent for Xolatryp Granted 30 Sep 2026 4:22PM $0.500 $0.495 fallen by 1%
$128 Cleansing Statement 25 Sep 2026 9:20AM $0.495 $0.495 fallen by 0%
$128 Application for quotation of securities - NYR 25 Sep 2026 9:17AM $0.495 $0.495 fallen by 0%
$128 Proposed issue of securities - NYR 21 Sep 2026 9:31AM $0.730 $0.495 fallen by 32.19%
$128 Proposed issue of securities - NYR 21 Sep 2026 9:31AM $0.730 $0.495 fallen by 32.19%
$128 Proposed issue of securities - NYR 21 Sep 2026 9:31AM $0.730 $0.495 fallen by 32.19%
$128 Proposed issue of securities - NYR 21 Sep 2026 9:31AM $0.730 $0.495 fallen by 32.19%
$128 Cap Raise Deck-Building the Future of TRPC-based Therapies 21 Sep 2026 9:31AM $0.730 $0.495 fallen by 32.19%
$128 Nyrada Successfully Raises AU$12.0 Million Via Placement 21 Sep 2026 9:31AM $0.730 $0.495 fallen by 32.19%
$128 Trading Halt 17 Sep 2026 9:14AM $0.730 $0.495 fallen by 32.19%
$128 Investor Presentation- Evans&Partners Small Cap Healthcare 16 Sep 2026 8:31AM $0.725 $0.495 fallen by 31.72%
$128 Change in substantial holding - M Azzi 28 Aug 2026 9:36AM $0.740 $0.495 fallen by 33.11%
$128 Cleansing Statement 24 Aug 2026 4:52PM $0.740 $0.495 fallen by 33.11%
$128 Application for quotation of securities - NYR 24 Aug 2026 4:50PM $0.740 $0.495 fallen by 33.11%
$128 Xolatryp Demonstrates Cardioprotection in Preclinical Study 21 Aug 2026 8:50AM $0.740 $0.495 fallen by 33.11%
$128 Nyrada Full Year Results FY2026 18 Aug 2026 1:08PM $0.725 $0.495 fallen by 31.72%
$128 Annual Report for year ended 30 June 2026 18 Aug 2026 1:08PM $0.725 $0.495 fallen by 31.72%
$128 Preliminary Final Report 18 Aug 2026 1:05PM $0.725 $0.495 fallen by 31.72%

1 - 25 of 521 results

Page 1 of 21

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.